LEUKOSEP – SOLX B ADDITIVE SOLUTION (Haemonetics Manufacturing Inc)
Welcome to the PulseAid listing for the LEUKOSEP – SOLX B ADDITIVE SOLUTION drug offered from Haemonetics Manufacturing Inc. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Haemonetics Manufacturing Inc |
NON-PROPRIETARY NAME: | SOLX B ADDITIVE SOLUTION |
SUBSTANCE NAME: | DEXTROSE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2013-05-15 |
END MARKETING DATE: | 0000-00-00 |
LEUKOSEP – SOLX B ADDITIVE SOLUTION HUMAN PRESCRIPTION DRUG Details:
Item Description | LEUKOSEP – SOLX B ADDITIVE SOLUTION from Haemonetics Manufacturing Inc |
LABELER NAME: | Haemonetics Manufacturing Inc |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 1.78(g/30mL) |
START MARKETING DATE: | 2013-05-15 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 53157-301_795f1082-9ede-47cb-9a22-5092787ecbb3 |
PRODUCT NDC: | 53157-301 |
APPLICATION NUMBER: | NDA110059 |
Other DEXTROSE Pharmaceutical Manufacturers / Labelers: